Pfizer has at all times been a heavy consumer of CROs, and over the previous few months it’s been ramping up its partnerships.
Final month, it doubled down on its current pact with Syneos Well being (the outcomes of the INC Analysis and inVentiv Well being merger in 2018), a couple of months after signing an analogous take care of Icon; now it’s doing the identical with PPD.
The U.S. Massive Pharma and the CRO have signed as much as a brand new three-year settlement to “present drug improvement companies to advance Pfizer’s portfolio”, the pair mentioned in a short replace. In response to the deal, Pfizer may also enhance this pact for a further two years.
RELATED: Pfizer indicators up for longer pact with Icon, pens further 2-year clause
Pfizer picked PPD as considered one of its “most popular” CROs again in 2015. Monetary phrases weren’t made public, as is normally the case with these offers.
“United in objective, we’re dedicated to constructing on our long-standing relationship with Pfizer with modern options, high quality execution and the dedication of our proficient groups to assist Pfizer ship thrilling new therapies,” mentioned David Simmons, PPD’s chairman and CEO.
“PPD is strategically positioned to proceed supporting Pfizer in its pursuit of breakthroughs that change sufferers’ lives. We’re privileged to take the subsequent steps collectively and contribute to Pfizer’s initiatives to realize a more healthy world.”